Medications for Atypical Hemolytic Uremic Syndrome
4 results
Bkemv (eculizumab-aeeb)
(eculizumab-aeeb)Amgen Inc
Usage: BKEMV is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adults who are anti-acetylcholine receptor antibody positive. Not for Shiga toxin E. coli related HUS.
Epysqli (eculizumab-aagh)
(Eculizumab-aagh)Samsung Bioepis Co., Ltd.
Usage: EPYSQLI is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy, and generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor antibody positive. Limitations apply for STEC-HUS.
Soliris (eculizumab)
(ECULIZUMAB)Alexion Pharmaceuticals Inc
Usage: SOLIRIS is indicated for treating paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome (aHUS) to inhibit thrombotic microangiopathy, generalized myasthenia gravis (gMG) in patients aged six and older, and neuromyelitis optica spectrum disorder (NMOSD) in anti-AQP4 positive adults.
Ultomiris (ravulizumab)
(ravulizumab)Alexion Pharmaceuticals Inc
Usage: ULTOMIRIS is indicated for treating adult and pediatric patients aged one month and older with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Additionally, it is used for adult patients with generalized myasthenia gravis (anti-AChR antibody-positive) and neuromyelitis optica spectrum disorder (AQP4 antibody-positive).